Opinion: STAT+: How pharma and biotech can keep innovating in a bear market

A bear market can put a damper on the pace of innovation in the short term, especially as access to equity capital becomes uncertain. But it can also be a…

Over the last decade, the biotech sector experienced the largest boom it has ever seen. Yet in just a few months in 2022, there has been a sharp reversal in the tone of capital markets towards biotech and beyond, plunging the industry into a bear market.

Having worked in the life sciences industry for the last 20-plus years in operational roles as a CFO and advisory roles as an investment banker, I know firsthand that bear markets can put a damper on the industry’s pace of innovation in the short term. But I’ve also learned that, with the right approach, companies can make the best of a bad situation to sharpen their focus and set the stage for a stronger trajectory on the other side.

Continue to STAT+ to read the full story…